Alemtuzumab for the prevention and treatment of graft-versus-host disease

@article{Kanda2011AlemtuzumabFT,
  title={Alemtuzumab for the prevention and treatment of graft-versus-host disease},
  author={Junya Kanda and Richard D. Lopez and David Alan Rizzieri},
  journal={International Journal of Hematology},
  year={2011},
  volume={93},
  pages={586-593}
}
Alemtuzumab is a humanized monoclonal antibody against the CD52 antigen, which is expressed on the surface of various hematopoietic cells such as B and T lymphocytes, and has been widely used for preventing acute graft-versus-host disease (GVHD) in allogeneic stem cell transplantation (SCT). Administration of 100 mg alemtuzumab before transplantation has resulted in a low incidence of acute GVHD in HLA-matched and mismatched transplantation from either related or unrelated donors. However… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag).

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2013
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED